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Exploiting the potential of antisense: beyond 
phosphorothioate oligodeoxynucleotides 
CA Stein 
Phosphorothioate oligodeoxynucleotides, designed as 
nuclease-resistant antisense agents, appear to have a 
number of surprising biological effects that are unrelated 
to their intended antisense activity. These effects may be 
useful in themselves, but must be understood for the full 
potential of antisense technology to be realized. 
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Antisense oligodeoxynucleotides can be used to specifi- 
cally inhibit the intracellular expression of, theoretically, 
any given gene. It has been estimated that the sequence 
of an oligodeoxynucleotide of 15-17 residues in length 
may be unique in the entire human genome. Thus, a 
short DNA sequence could be used to form a specific 
mRNA-DNA hybrid, blocking the expression of that 
gene and that gene only. The attractions of such 
approaches have been obvious from the start, but their 
difficulties are only now becoming clear. Here I review 
some of the unexpected findings that make it difficult to 
interpret some antisense experiments, the potential uses 
of these unexpected findings, and the consequences for 
antisense design. 
Successes and prospects of antisense Figure 1 
The power and elegance of the antisense approach to 
gene regulation has been demonstrated numerous times, 
both in tissue culture and in viva [l]. Antisense 
oligodeoxynucleotides are now being used in clinical 
trials as therapeutic anti-neoplastic or anti-HIV agents. 
Target mRNAs have included a conserved region of the 
~53 mRNA, in an attempt to treat acute myelogenous 
leukemia [Z], and the HIV-l gag mRNA [3]. Although 
clinical efficacy has not yet been shown, one striking 
demonstration that antisense oligodeoxynucleotide tech- 
nology can produce useful data was provided by Methia 
et a/. [4]. Using a targeted antisense approach, these 
authors proved that the protooncogene c-mpl’ was the 
cell-surface receptor for a thrombopoietic factor. They 
used this information and affinity chromatography to 
isolate thrombopoietin, and then cloned and sequenced 
the gene that encodes it, and produced the recombinant 
protein. Thrombopoietin is now being used in clinical 
trials. As several tens of thousands of human genes will 
be sequenced over the next decade, it becomes essential 
to have a rapid, high through-put, relatively inexpensive 
method to determine their cellular function. Antisense 
Structures of the normal phosphodiester linkage in DNA (top) and the 
nuclease-resistant phosphorothioate linkage (bottom) used in 
antisense oligodeoxynucleotides. 
oligodeoxynucleotide technology can, in theory, provide 
such a method. 
Synthetic oligodeoxynucleotides 
Normal DNA is not the ideal antisense agent, however, 
because it readily undergoes nuclease digestion, caused 
primarily by 3’-5’ exonucleases, but also by endo- 
nucleases. To avoid this problem, Stec and collaborators 
[S] synthesized phosphorothioate oligodeoxynucleo- 
tides. These compounds have a sulfur for oxygen 
replacement at a non-bridging position at each phospho- 
rus atom in the molecule (Fig. 1). They were originally 
synthesized by sulfurization of the phosphite linkage 
formed at the 5’ terminus of the growing oligodeoxynu- 
cleotide by a solution of elemental sulfur in carbon 
disulfide/pyridine/l % triethylamine. But this mixture 
tended to clog the automated synthesizer, and the sulfu- 
rization reagent in most common use today is a solution 
of tetraethylthiuram disulfide in acetonitrile. An alterna- 
tive reagent, 3H-1,2-benzodithiol-3-one l,l-dioxide, also 
used with acetonitrile, has been developed by Beaucage 
and collaborators [6]. In both cases, sulfurization pro- 
ceeds rapidly and is highly efficient, although reverse- 
phase high-performance liquid chromatography 
purification of the product is commonly performed, and 
is a virtual necessity for removing cytotoxic reagents 
used in the synthesis reaction. 
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Properties of phosphorothioate oligodeoxynudeotides 
Phosphorothioate oligodeoxynucleotides share many of the 
properties of phosphodiester polymers. Although they are 
nuclease-resistant (though not nuclease-proof), they retain 
the aqueous solubility of the parent phosphodiester. The 
modified oligodeoxynucleotides hybridize strongly to their 
target mRNA, although not as strongly as does the parent 
molecule. For example, each G-C and A-T base pair of a 
phosphorothioate oligodeoxynucleotide contributes -2.5 “C 
and 1.5 “C, respectively, to the duplex melting temperature 
(T,), compared to 4 “C and 2 “C, respectively, for phospho- 
diesters. This results in a AH of melting for a phosphoroth- 
ioate DNA-mRNA duplex that is substantially lower than 
that of a phosphodiester molecule of the same sequence [7]. 
Most importantly, phosphorothioate oligodeoxynucleotides, 
like their phosphodiester counterparts, can elicit the activ- 
ity of RNAse H. This enzyme, found predominantly in the 
cell nucleus, cleaves the mRNA strand of an mRNA-DNA 
duplex. The oligodeoxynucleotide can thus be thought of 
as a catalyst for mRNA cleavage. 
Here we come to the first puzzle of how antisense com- 
pounds work. RNAse H activity has been proven to be a 
major contributor to antisense activity in Xenopus oocytes, 
and this is also believed to be true in mammalian cells. If 
this is so, it should be possible to isolate mRNA cleavage 
fragments of the appropriate length from cells treated with 
an antisense oligodeoxynucleotide. It has generally been 
difficult to find such fragments. Recently, RNAse H cleav- 
age fragments of ~53 and bcr-abl mRNA have been 
detected in streptolysin-0 permeabilized KY01 chronic 
myelogenous leukemia cells after treatment with appro- 
priate antisense (but not control) oligodeoxynucleotides 
[8]. Unfortunately, it is unclear to what extent these data 
can be extrapolated to other cellular systems. 
In using phosphorothioate oligodeoxynucleotides, one 
must consider the chirality at the phosphorus atom created 
by the sulfur for oxygen substitution. LaPlanche et al. [9] 
studied diastereomerically pure, duplex DNA with either 
a single Rp or Sp phosphorothioate linkage in the 
sequence d(GG,AATTCC),. The value of T, for the 
Rp-Rp duplex was diminished by 2.4 “C relative to the 
parent phosphodiester, whereas the T, of the Sp-Sp 
duplex was almost identical to it. This is probably because, 
for the Rp form, the P-S bond axis lies in the major groove 
of the duplex, whereas for the Sp diastereomer, the sulfur 
atom lies on the face of the sugar-phosphate backbone, ori- 
ented ‘out’ of the major groove. Unfortunately, the Sp 
diastereomer is much more sensitive to the nucleases 
found in mammalian cells than is the Rp form. 
The sulfurizing reagents commonly used in the auto- 
mated phosphorothioate synthesis produce an approxi- 
mately random mixture of Rp and Sp stereoisomers. In 
any given 28-base oligodeoxynucleotide, for example, 2z7 
stereoisomers may be present. To circumvent this 
problem, Stec et al. [lo] designed a stereocontrolled syn- 
thesis of P-chiral phosphorothioates using a novel oxathi- 
aphospholane synthon. Using this technology, and with 
subsequent modifications, it is possible to obtain mil- 
ligram quantities of phosphorothioate oligodeoxy- 
nucleotides with >90 % (and, depending on the sequence, 
in some cases >95 %) stereopurity. The biological conse- 
quences of the improvement in the stereopurity of phos- 
phorothioate oligodeoxynucleotides are currently being 
evaluated in a number of test systems. 
The confounding effects of heparin-binding proteins 
There is no question that phosphorothioate oligodeoxy- 
nucleotides can, under certain conditions, act as antisense 
reagents. One dramatic example of this was provided by 
Dean and Mackay [ll]. They synthesized a ZO-base 
phosphorothioate oligodeoxynucleotide targeted to the 
translation initiation codon of the mRNA encoding the 
murine protein kinase C-a isoform in liver, and adminis- 
tered it systemically to SK-1 hairless mice. At a concentra- 
tion of 400 nM, the oligomer reversibly and sequence 
specifically decreased the intra-hepatocyte concentration 
of PKC-cx mRNA and protein by 70-80 %, whereas the 
levels of the 6, E and 5 isoforms were unchanged. 
But phosphorothioate oligodeoxynucleotides, despite their 
physicochemical similarity to normal DNA, have an unex- 
pected property that seriously complicates interpretation of 
experimental data obtained from their use. They bind 
avidly to proteins, particularly (and, as far as we know, 
exclusively) to those proteins that bind the negatively 
charged glycosaminoglycan heparin [12]. In general, the 
dissociation constant (K,) of a phosphorothioate oligo- 
deoxynucleotide-protein complex is approximately two to 
three orders of magnitude lower than that of the complex 
formed by the parent phosphodiester molecule. This may 
be a reflection of the fact that, at least for the complex 
formed between a phosphorothioate oligodeoxynucleotide 
and basic fibroblast growth factor (bFGF), the rate of disso- 
ciation of the phosphorothioate molecule from the protein 
appears to be extremely slow. 
Examples of heparin-binding proteins now known to 
bind directly to phosphorothioate oligodeoxynucleotides 
include members of the FGF family, including bFGF, 
acidic FGF and FGF4 (K-fgf/hst) [12], and other heparin- 
binding growth factors, including platelet-derived growth 
factor (PDGF), and vascular endothelial growth factor 
(VEGF). PDGF and VEGF have been implicated in regu- 
lating the rate of growth of certain tumor cells and in the 
process of angiogenesis. Phosphorothioate oligodeoxy- 
nucleotides do not seem to bind to epidermal growth factor 
(EGF), which binds only weakly, if at all, to heparin. It is 
interesting to note that there seems to be no difference 
between the affinities of all-Rp, all-Sp or stereorandom 
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forms of phosphorothioate oligodeoxynucleotides for 
bFGF or for several other proteins [13]. The reasons for 
this are not yet entirely clear. 
Heparin-binding cell-surface receptors 
It has become apparent more recently that at least some 
phosphorothioate oligodeoxynucleotides can also bind to 
several cell-surface receptors, including the epidermal 
growth factor receptor (EGFR) and the VEGF receptor 
(flk-1) (P Rockwell, N. Goldstein, L.M. Zhang & C.A.S., 
unpublished data), which both bind to heparin. Non- 
sequence-specific phosphorothioate oligodeoxynucleo- 
tides can stimulate EGFR phosphorylation in the absence 
of EGF in the KB epidermoid carcinoma line, but can 
antagonize ligand-mediated activation of EGFR in the 
presence of the growth factor. The modified oligodeoxy- 
nucleotides partially block the binding of certain anti- 
receptor monoclonal antibodies to flk-1, and block 
ligand-induced phosphorylation of this receptor. Zn viva, a 
Z&base phosphorothioate homopolymer of cytidine 
(SdC,,) almost entirely blocked the growth of implanted 
GBM-18 (glioblastoma multiforme) cells in athymic nude 
mice. The effect of SdC2s was similar to that of a mono- 
clonal antibody targeted to flk-1 (P. Rockwell, N. Gold- 
stein, L.M. Zhang & C.A.S., unpublished data). 
The mechanism of this inhibition has nothing to do with 
the classical antisense strategy, that is, the interaction of 
the oligodeoxynucleotide with mRNA, and we therefore 
term these effects ‘non-sequence-specific’. This does not 
mean, however, that different phosphorothioate oligo- 
deoxynucleotides all have the same level of inhibitory 
activity. Undoubtedly there will be some level of sequence 
selectivity in these effects, as discussed below. 
Phosphorothioate oligodeoxynucleotides block cellular 
adhesion by multiple mechanisms 
Phosphorothioate oligodeoxynucleotides have a variety 
of effects on cellular adhesion, which have recently been 
Figure 2 
shown to be non-sequence specific [14]. For example, 
there are many reports that these molecules can block 
heterotypic cellular adhesion to plastic substrata. Interest- 
ingly, this non-sequence-specific block to adhesion can be 
almost completely overcome by pretreatment of the plastic 
with either of the extracellular matrix proteins laminin or 
libronectin, both of which bind to heparin. When the con- 
centration of the phosphorothioate oligodeoxynucleotides 
is high enough, however, they can also block cellular adhe- 
sion to laminin. These compounds bind to the A (or) 
subunit (Mr = 400 kDa) of laminin at or near the heparin- 
binding site; this blocks the ability of laminin to bind to its 
ligand sulfatide (galactosyl ceramide sulfate), a compound 
secreted by cells and on which they can spread and grow. 
Phosphorothioate oligodeoxynucleotides also bind to fibro- 
nectin, and some data suggest that they bind to the 
libronectin receptor as well. Although these effects were 
not the ones expected, it may be possible to exploit them 
for experimental and clinical purposes. 
Effects on restenosis 
Considering all the various non-sequence-specific effects 
of the phosphorothioate oligodeoxynucleotides, it seems 
likely that these compounds could also prove useful as 
agents that block coronary restenosis after balloon angio- 
plast, since inhibition of the effects of growth factors of 
the FGF family should block smooth muscle proliferation 
(Fig. 2). Indeed, these compounds have already been eval- 
uated as sequence-specific inhibitors of restenosis in a rat 
model [15]. The phosphorothioate oligodeoxynucleotides 
used in this study were targeted to the mRNA of the c-myb 
protooncogene, which has been implicated in the prolifer- 
ation of smooth muscle cells. The results initially 
appeared positive, but their interpretation is complicated 
by the fact that the antisense c-myb phosphorothioate 
oligodeoxynucleotide contains a sequence motif consist- 
ing of four contiguous guanosine bases. Burgess et al. [16] 
have provided evidence that virtually all of the activity of 
the anti-c-myb oligomer against restenosis resides in this 
of the activity of heparin-binding growth matrix of the artery wall); inhibition of growth 
factors such as bFGF, PDGF and VEGF factor receptors such as the EGF receptor; 
(shown sequestered in the extracellular and inhibition of cellular adhesion, for 
example by binding to the extracellular matrix 
proteins laminin or fibronectin, or possibly to 
the fibronectin receptor. 
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motif alone, suggesting that the inhibition of proliferation 
is not a true antisense effect. 
We have recently shown [17] that the non-sequence-spe- 
cific phosphorothioate SdC,, is a potent inhibitor of 
smooth muscle cell proliferation in response to EGF and 
bFGF, and that it is an effective inhibitor of restenosis 
when applied to the adventitial surface of a rat carotid 
artery in a pluronic gel after balloon angioplasty. On the 
basis of evidence of this type, it seems obvious that the 
biological activity of phosphorothioate oligodeoxynucleo- 
tides is based on their pleiotropic effects; at least in some 
cases, these are a composite of sequence-specific and non- 
sequence-specific effects. 
Influence of G-quartets 
The binding of phosphorothioate oligodeoxynucleotides to 
proteins, and in particular to heparin-binding proteins, 
seems to be dependent on the length of the oligomer, and 
to some extent on the sequence as well. For example, 
phosphorothioate oligodeoxynucleotides that contain the 
G-quartet motif (four contiguous guanosine residues) are 
more potent non-sequence-specific inhibitors, probably 
because they bind more strongly to proteins (e.g., to 
recombinant soluble CD4, bFGF or the laminin or chain). 
Some phosphorothioate oligodeoxynucleotides (e.g., 
SdT,G,T, [IS]) actually form parallel-stranded quadruple 
helices by Hoogsteen base-pairing, which may account for 
the fact that this compound binds more strongly to recom- 
binant soluble gp120 than other phosphorothioate oligo- 
deoxynucleotides [19]. Our understanding of the role of 
the G-quartet motif in ‘non-sequence specific’ effects is 
incomplete, however. For example, at least some 
phosphorothioate oligodeoxynucleotides containing the G- 
quartet motif have increased avidity for protein despite the 
demonstrable absence of the higher order structure caused 
by the formation of Hoogsteen base pairs ([12], C.A.S. and 
coworkers, unpublished data). Furthermore, Maltese et al 
[ZO] have recently shown that the extent of the ‘non- 
sequence-specific’ effects observed with phosphorothioate 
oligodeoxynucleotides containing a G-quartet motif is 
dependent on the nature of the flanking sequences. It can 
thus be difficult to define appropriate control oligo- 
deoxynucleotides for an experiment in which the antisense 
construct contains a G-quartet motif. 
Questions of cellular internalization 
For sequence-specific interactions with cellular mRNA to 
occur, the antisense construct must be taken up into the 
cell. The process of cellular internalization and compart- 
mentalization of phosphodiester and phosphorothioate 
oligodeoxynucleotides seems to depend on non-sequence- 
specific interactions, however. The first step in internaliza- 
tion takes place at the cell surface, where charged 
oligodeoxynucleotides adsorb to binding sites on the cell 
membrane. In the cell lines examined thus far, ~90 %  of 
these sites are heparin-binding sites, and may include, as 
described above, Mac-l, EGFR and flk-1. Oligodeoxy- 
nucleotides that are uncharged, such as methyl- 
phosphonates, and peptide nucleic acids, in which the 
nitrogenous bases are covalently linked to a polypeptide 
scaffold, cannot bind to heparin-binding proteins, do not 
adsorb well to the cell surface, and tend not to be internal- 
ized in cells to a great extent. Since even non-charged 
oligodeoxynucleotides cannot passively diffuse through 
cell membranes, they must be internalized by fluid-phase 
endocytosis (also known as pinocytosis). This process 
tends to be inefficient, particularly for non-adherent cells. 
Thus, it may be difficult to construct antisense agents that 
are efficiently taken up by cells and yet fail to bind to 
heparin-binding proteins. There is some recent evidence, 
however, for the existence in some cells of a membrane 
channel that transports oligodeoxynucleotides [Zl]. 
Future directions 
Where does this leave us? The advantages of phospho- 
rothioate oligodeoxynucleotides are clear: they are soluble 
and nuclease resistant, form stable duplexes with mRNA, 
elicit RNAse H activity, adsorb well to cell membranes, 
probably by binding to heparin-binding sites, and are 
internalized efficiently (although their ability to penetrate 
endosomes or lysosomes in the absence of cationic lipids 
seems to be limited). On the other hand, phosphoro- 
thioates longer than 15 bases can have effects that are 
P-chirality-independent, non-sequence-specific, and which 
may confound the interpretation of experimental results. 
At least in some cases, these effects can be seen at a con- 
centration of no greater than 2 ~.LM. Furthermore, it may 
occasionally be impossible to establish appropriate control 
sequences when phosphorothioate oligodeoxynucleotides 
containing certain sequence motifs (e.g., G-quartets) are 
used. Thus, phosphorothioates have their limitations, 
although this by no means rules out the possibility that 
they may be extremely active anti-proliferative, clinical 
therapeutic agents. 
There is no question that there is a great deal of room in 
this field for creative chemistry. The recent syntheses and 
early development of C5-propyne phosphorothioate [ZZ] 
and of phosphoroamidate oligodeoxynucleotides [23] 
provide some examples. The phosphoroamidates contain 
an oxygen for nitrogen substitution at a bridging position 
on phosphorus. They seem to be potent antisense 
reagents with little or none of the non-sequence-specific 
binding of the phosphorothioates. They are, however, 
difficult to synthesize in high yield. 
It is also possible that combinations of various classes of 
backbones, incorporated into what have been called 
chimeric oligodeoxynucleotides, will eventually render 
the ultimate antisense construct more efficacious, with 
fewer non-sequence-specific effects. It is possible that 
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the chimera will have to be optimized for variables such 
as targeted cell type and oligomer sequence, and may 
well have to make use of chemistries that are not yet 
available. Although antisense technology is now entering 
its second decade, our understanding of this compli- 
cated, controversial field is, to all intents and purposes, 
still in its infancy. 
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